Does the media favor CING or TRDA?

In the previous week, Entrada Therapeutics had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for Entrada Therapeutics and 1 mentions for Cingulate. Entrada Therapeutics' average media sentiment score of 1.60 beat Cingulate's score of 0.61 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cingulate 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is CING or ZNTL more profitable?

Zentalis Pharmaceuticals' return on equity of -53.61% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% Zentalis Pharmaceuticals N/A -53.61% -40.67%

Does the media prefer CING or ZNTL?

In the previous week, Cingulate and Cingulate both had 1 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 0.76 beat Cingulate's score of 0.61 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cingulate 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CING or IVVD more profitable?

Cingulate has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% Invivyd -138.90% -53.48% -41.56%

Does the media refer more to CING or IVVD?

In the previous week, Invivyd had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for Invivyd and 1 mentions for Cingulate. Cingulate's average media sentiment score of 0.61 beat Invivyd's score of 0.50 indicating that Cingulate is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cingulate 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MGNX or CING more profitable?

Cingulate has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. MacroGenics' return on equity of -147.80% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -44.79% -147.80% -28.40% Cingulate N/A -365.15% -158.55%

Does the media prefer MGNX or CING?

In the previous week, MacroGenics had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for MacroGenics and 1 mentions for Cingulate. Cingulate's average media sentiment score of 0.61 beat MacroGenics' score of 0.00 indicating that Cingulate is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cingulate 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CING or ACIU more profitable?

Cingulate has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. AC Immune's return on equity of -125.26% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% AC Immune -1,788.02% -125.26% -40.85%

Does the media refer more to CING or ACIU?

In the previous week, Cingulate and Cingulate both had 1 articles in the media. AC Immune's average media sentiment score of 1.16 beat Cingulate's score of 0.61 indicating that AC Immune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cingulate 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AC Immune 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cingulate (CING) Competitors

$4.83 -0.11 (-2.23%)

Closing price 04:00 PM Eastern

Extended Trading

$4.88 +0.05 (+1.04%)

As of 07:50 PM Eastern

Compare

CING vs. TRDA, ZNTL, IVVD, MGNX, and ACIU

Should you buy Cingulate stock or one of its competitors? MarketBeat compares Cingulate with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cingulate include Entrada Therapeutics (TRDA), Zentalis Pharmaceuticals (ZNTL), Invivyd (IVVD), MacroGenics (MGNX), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry.

How does Cingulate compare to Entrada Therapeutics?

Cingulate (NASDAQ:CING) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Cingulate has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 5.3% of Cingulate shares are owned by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cingulate currently has a consensus price target of $27.33, indicating a potential upside of 465.91%. Entrada Therapeutics has a consensus price target of $17.50, indicating a potential upside of 141.71%. Given Cingulate's stronger consensus rating and higher possible upside, equities analysts clearly believe Cingulate is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cingulate has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
Entrada Therapeutics	$25.42M	11.06	-$143.75M	-$3.99	N/A

In the previous week, Entrada Therapeutics had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for Entrada Therapeutics and 1 mentions for Cingulate. Entrada Therapeutics' average media sentiment score of 1.60 beat Cingulate's score of 0.61 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cingulate	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cingulate has a beta of -0.85, indicating that its share price is 185% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market.

Summary

Entrada Therapeutics beats Cingulate on 9 of the 14 factors compared between the two stocks.

How does Cingulate compare to Zentalis Pharmaceuticals?

Cingulate (NASDAQ:CING) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Zentalis Pharmaceuticals' return on equity of -53.61% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

Cingulate has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
Zentalis Pharmaceuticals	$67.43M	3.89	-$137.06M	-$1.73	N/A

In the previous week, Cingulate and Cingulate both had 1 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 0.76 beat Cingulate's score of 0.61 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cingulate	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

41.3% of Cingulate shares are owned by institutional investors. 5.3% of Cingulate shares are owned by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cingulate has a beta of -0.85, indicating that its share price is 185% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

Cingulate presently has a consensus target price of $27.33, indicating a potential upside of 465.91%. Zentalis Pharmaceuticals has a consensus target price of $5.83, indicating a potential upside of 58.51%. Given Cingulate's stronger consensus rating and higher possible upside, equities analysts plainly believe Cingulate is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Cingulate beats Zentalis Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Cingulate compare to Invivyd?

Cingulate (NASDAQ:CING) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Cingulate currently has a consensus target price of $27.33, suggesting a potential upside of 465.91%. Invivyd has a consensus target price of $8.00, suggesting a potential upside of 755.98%. Given Invivyd's higher probable upside, analysts clearly believe Invivyd is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cingulate has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
Invivyd	-138.90%	-53.48%	-41.56%

In the previous week, Invivyd had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for Invivyd and 1 mentions for Cingulate. Cingulate's average media sentiment score of 0.61 beat Invivyd's score of 0.50 indicating that Cingulate is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cingulate	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cingulate has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
Invivyd	$53.43M	5.15	-$52.49M	-$0.31	N/A

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 5.3% of Cingulate shares are owned by insiders. Comparatively, 12.3% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cingulate has a beta of -0.85, suggesting that its stock price is 185% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

Summary

Invivyd beats Cingulate on 9 of the 14 factors compared between the two stocks.

How does Cingulate compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 5.3% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, MacroGenics had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for MacroGenics and 1 mentions for Cingulate. Cingulate's average media sentiment score of 0.61 beat MacroGenics' score of 0.00 indicating that Cingulate is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cingulate	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cingulate has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. MacroGenics' return on equity of -147.80% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
Cingulate	N/A	-365.15%	-158.55%

MacroGenics currently has a consensus price target of $5.50, indicating a potential upside of 17.27%. Cingulate has a consensus price target of $27.33, indicating a potential upside of 465.91%. Given Cingulate's stronger consensus rating and higher possible upside, analysts clearly believe Cingulate is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

MacroGenics has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.85, meaning that its share price is 185% less volatile than the broader market.

Cingulate has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.99	-$74.62M	-$1.10	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

Summary

MacroGenics beats Cingulate on 8 of the 14 factors compared between the two stocks.

How does Cingulate compare to AC Immune?

Cingulate (NASDAQ:CING) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Cingulate currently has a consensus price target of $27.33, indicating a potential upside of 465.91%. AC Immune has a consensus price target of $7.50, indicating a potential upside of 206.12%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Cingulate and Cingulate both had 1 articles in the media. AC Immune's average media sentiment score of 1.16 beat Cingulate's score of 0.61 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cingulate	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AC Immune	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cingulate has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. AC Immune's return on equity of -125.26% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
AC Immune	-1,788.02%	-125.26%	-40.85%

Cingulate has a beta of -0.85, indicating that its share price is 185% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market.

Cingulate has higher earnings, but lower revenue than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
AC Immune	$4.31M	57.85	-$85.03M	-$0.82	N/A

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 5.3% of Cingulate shares are owned by company insiders. Comparatively, 4.6% of AC Immune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cingulate and AC Immune tied by winning 7 of the 14 factors compared between the two stocks.

Get Cingulate News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CING vs. The Competition

Export

Metric	Cingulate	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$66.54M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-1.14	19.75	24.92	23.97
Price / Sales	N/A	329.42	528.81	109.59
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	15.58	8.29	10.79	6.50
Net Income	-$22.45M	$23.85M	$3.56B	$336.88M
7 Day Performance	1.90%	5.21%	1.67%	-0.22%
1 Month Performance	8.05%	2.19%	0.43%	0.77%
1 Year Performance	19.55%	60.99%	32.84%	31.57%

Cingulate Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CING Cingulate	3.0409 of 5 stars	$4.83 -2.2%	$27.33 +465.9%	+19.3%	$66.54M	N/A	N/A	20	Gap Up
TRDA Entrada Therapeutics	3.9886 of 5 stars	$6.55 -0.3%	$17.50 +167.2%	-0.7%	$254.27M	$25.42M	N/A	110	Positive News
ZNTL Zentalis Pharmaceuticals	2.2464 of 5 stars	$3.57 -5.7%	$5.83 +63.6%	+182.3%	$253.79M	$67.43M	N/A	160	Positive News
IVVD Invivyd	2.7867 of 5 stars	$0.85 -2.7%	$8.00 +846.7%	+22.6%	$249.24M	$53.43M	N/A	100
MGNX MacroGenics	1.53 of 5 stars	$3.89 -5.9%	$5.50 +41.6%	+249.6%	$246.93M	$149.50M	N/A	430	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CING) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cingulate (CING) Competitors

CING vs. TRDA, ZNTL, IVVD, MGNX, and ACIU

How does Cingulate compare to Entrada Therapeutics?

Summary

How does Cingulate compare to Zentalis Pharmaceuticals?

Summary

How does Cingulate compare to Invivyd?

Summary

How does Cingulate compare to MacroGenics?

Summary

How does Cingulate compare to AC Immune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CING vs. The Competition

Cingulate Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cingulate (CING) Competitors

CING vs. TRDA, ZNTL, IVVD, MGNX, and ACIU

How does Cingulate compare to Entrada Therapeutics?

Is CING or TRDA more profitable?

Do insiders and institutionals believe in CING or TRDA?

Do analysts prefer CING or TRDA?

Which has stronger valuation & earnings, CING or TRDA?

Does the media favor CING or TRDA?

Which has more volatility and risk, CING or TRDA?

Summary

How does Cingulate compare to Zentalis Pharmaceuticals?

Is CING or ZNTL more profitable?

Which has better valuation & earnings, CING or ZNTL?

Does the media prefer CING or ZNTL?

Do institutionals and insiders believe in CING or ZNTL?

Which has more risk and volatility, CING or ZNTL?

Do analysts prefer CING or ZNTL?

Summary

How does Cingulate compare to Invivyd?

Do analysts recommend CING or IVVD?

Is CING or IVVD more profitable?

Does the media refer more to CING or IVVD?

Which has preferable valuation & earnings, CING or IVVD?

Do institutionals & insiders hold more shares of CING or IVVD?

Which has more volatility and risk, CING or IVVD?

Summary

How does Cingulate compare to MacroGenics?

Do institutionals and insiders have more ownership in MGNX or CING?

Does the media prefer MGNX or CING?

Is MGNX or CING more profitable?

Do analysts prefer MGNX or CING?

Which has more risk & volatility, MGNX or CING?

Which has preferable valuation and earnings, MGNX or CING?

Summary

How does Cingulate compare to AC Immune?

Do analysts rate CING or ACIU?

Does the media refer more to CING or ACIU?

Is CING or ACIU more profitable?

Which has more risk and volatility, CING or ACIU?

Which has preferable earnings and valuation, CING or ACIU?

Do institutionals and insiders believe in CING or ACIU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CING vs. The Competition

Cingulate Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools